These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 17302523

  • 1. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T, Billich A, Brinkmann V.
    Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
    [Abstract] [Full Text] [Related]

  • 2. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V.
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [Abstract] [Full Text] [Related]

  • 3. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K.
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J, Hartung HP.
    Clin Neuropharmacol; 2010 Jun; 33(2):91-101. PubMed ID: 20061941
    [Abstract] [Full Text] [Related]

  • 5. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K, Adachi K.
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [Abstract] [Full Text] [Related]

  • 6. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 7. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, Chun J.
    Proc Natl Acad Sci U S A; 2011 Jan 11; 108(2):751-6. PubMed ID: 21177428
    [Abstract] [Full Text] [Related]

  • 8. Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
    Hiestand PC, Rausch M, Meier DP, Foster CA.
    Prog Drug Res; 2008 Jan 11; 66():361, 363-81. PubMed ID: 18416311
    [Abstract] [Full Text] [Related]

  • 9. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
    Soliven B, Miron V, Chun J.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
    [Abstract] [Full Text] [Related]

  • 10. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K.
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr 22; 32(2):92-101. PubMed ID: 19404007
    [Abstract] [Full Text] [Related]

  • 11. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
    Chiba K.
    Pharmacol Ther; 2005 Dec 22; 108(3):308-19. PubMed ID: 15951022
    [Abstract] [Full Text] [Related]

  • 12. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 22; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 13. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
    Kipp M, Amor S.
    Mult Scler; 2012 Mar 22; 18(3):258-63. PubMed ID: 22383435
    [Abstract] [Full Text] [Related]

  • 14. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T, Brinkmann V.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [Abstract] [Full Text] [Related]

  • 15. Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.
    Natarajan V, Dudek SM, Jacobson JR, Moreno-Vinasco L, Huang LS, Abassi T, Mathew B, Zhao Y, Wang L, Bittman R, Weichselbaum R, Berdyshev E, Garcia JG.
    Am J Respir Cell Mol Biol; 2013 Jul 22; 49(1):6-17. PubMed ID: 23449739
    [Abstract] [Full Text] [Related]

  • 16. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A, Kihara Y, Chun J.
    J Neurol Sci; 2013 May 15; 328(1-2):9-18. PubMed ID: 23518370
    [Abstract] [Full Text] [Related]

  • 17. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L, Vécsei L.
    Ideggyogy Sz; 2012 Mar 30; 65(3-4):83-100. PubMed ID: 23136726
    [Abstract] [Full Text] [Related]

  • 18. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
    Brinkmann V.
    Pharmacol Ther; 2007 Jul 30; 115(1):84-105. PubMed ID: 17561264
    [Abstract] [Full Text] [Related]

  • 19. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function.
    Brinkmann V, Cyster JG, Hla T.
    Am J Transplant; 2004 Jul 30; 4(7):1019-25. PubMed ID: 15196057
    [Abstract] [Full Text] [Related]

  • 20. Molecular targets of FTY720 (fingolimod).
    Pitman MR, Woodcock JM, Lopez AF, Pitson SM.
    Curr Mol Med; 2012 Dec 30; 12(10):1207-19. PubMed ID: 22834825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.